首页 | 本学科首页   官方微博 | 高级检索  
检索        


The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells
Authors:Christian Mayr  Andrej Wagner  Magdalena Loeffelberger  Daniela Bruckner  Martin Jakab  Frieder Berr  Pietro Di Fazio  Matthias Ocker  Daniel Neureiter  Martin Pichler  Tobias Kiesslich
Abstract:BMI1 is a core component of the polycomb repressive complex 1 (PRC1) and is up-regulated in biliary tract cancer (BTC), contributing to aggressive clinical features. In this study we investigated the cytotoxic effects of PTC-209, a recently developed inhibitor of BMI1, in BTC cells. PTC-209 reduced overall viability in BTC cell lines in a dose-dependent fashion (0.04 - 20 μM). Treatment with PTC-209 led to slightly enhanced caspase activity and stop of cell proliferation. Cell cycle analysis revealed that PTC-209 caused cell cycle arrest at the G1/S checkpoint. A comprehensive investigation of expression changes of cell cycle-related genes showed that PTC-209 caused significant down-regulation of cell cycle-promoting genes as well as of genes that contribute to DNA synthesis initiation and DNA repair, respectively. This was accompanied by significantly elevated mRNA levels of cell cycle inhibitors. In addition, PTC-209 reduced sphere formation and, in a cell line-dependent manner, aldehyde dehydrogease-1 positive cells. We conclude that PTC-209 might be a promising drug for future in vitro and in vivo studies in BTC.
Keywords:biliary tract cancer  PRC1  PTC-209  cell cycle arrest  BMI1
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号